Enfermedades Infecciosas y Microbiologia Clinica, vol.38, no.10, pp.471-473, 2020 (SCI-Expanded)
© 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología ClínicaIntroduction: Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients. Methods: In this study the effectiveness and safety of tigecycline in children was assessed retrospectively. Results: A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2–32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse. Conclusion: Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria.